Oregon § 646A.696 Report to Health Care Cost Growth Target program and Legislative Assembly; contents of report

Oregon Statutes

§ 646A.696 — Report to Health Care Cost Growth Target program and Legislative Assembly; contents of report

Oregon § 646A.696

Vol.16

Title 50Trade Regulations and Practices

Ch. 646ATrade Regulation

This text of Oregon § 646A.696 (Report to Health Care Cost Growth Target program and Legislative Assembly; contents of report) is published on Counsel Stack Legal Research, covering Oregon primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook

Or. Rev. Stat. § 646A.696 (2026).

Text

No later than December 31 of each year, the Prescription Drug Affordability Board shall report to the Health Care Cost Growth Target program established in ORS 442.386 and to the interim committees of the Legislative Assembly related to health, in the manner provided in ORS 192.245, the following information:

(1)Price trends for the list of prescription drugs provided to the board by the Department of Consumer and Business Services under ORS 646A.694 (1);

(2)The prescription drugs that were reviewed under ORS 646A.694 (1);

(3)The status of the generic drug market as described in ORS 646A.697; and

(4)Recommendations, if any, for legislative changes necessary to make prescription drug products more affordable in this state.

Free access — add to your briefcase to read the full text and ask questions with AI

No later than December 31 of each year, the Prescription Drug Affordability Board shall report to the Health Care Cost Growth Target program established in ORS 442.386 and to the interim committees of the Legislative Assembly related to health, in the manner provided in ORS 192.245, the following information:
(1) Price trends for the list of prescription drugs provided to the board by the Department of Consumer and Business Services under ORS 646A.694 (1);
(2) The prescription drugs that were reviewed under ORS 646A.694 (1);
(3) The status of the generic drug market as described in ORS 646A.697; and
(4) Recommendations, if any, for legislative changes necessary to make prescription drug products more affordable in this state.